The RealReal: Strong Customer Adds, But The Stock Has Run Too Hot (Rating Downgrade)
After a strong rebound, The RealReal is ripe for a correction. See why REAL stock could fall to $4.50-$5.00 before becoming a ...
Santé log19 小时
Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2024 Financial Results
Net product sales of CAPLYTA were $680.5 million for the full year 2024. This represents an increase of 47% compared to 2023. Net product sales of CAPLYTA were $199.2 million for the fourth quarter of ...